AI
Saturday, June 15, 2024 5:43:45 PM
You have to know little about what you are playing if you don't want to end up with losing or being broke. Do you see the following symbols? Do you know what they are? These are just some examples of tumor-associated peptides bonded with MHC Class 1&2 molecules on dendrtic cell surface. These are the target information that t-cells are going to use to hunt down cancer cells. You can simply grab one and google it to see if researcher have talked about those peptides. If not, that means they were not found before NWBO found them. Do you know the significance of these findings?
DAVTYTEHAK
TPFGAYGGLLK
KTQDQISNIK
WNFPSPFYR
QVVNIPSFIVR
AVGPASILK
SSHNLAVHR
EPAAPVSIQR
EVTFVPGLYK
DTPGFIVNR
ETLPAEODLTTK
ESYEVSLTQK
DVSPFDHSR
EAVRPGVLR
GVFHQTVSR
GTLEQIMEK
KLYDIDVAK
KAHLGTALK
EAYDRDFLAR
ESILGGVLK
DSFPWEVPK
LSYNTASNK
VPAPFKPITR
YGFYTHVFR
DVFEAFYKK
AM[OX]EGIFIKPSVEPSAGHDEL
EQLGPVTQEFIIVDNLEKETEGLR
1VETRDGQVINETSQHHDDLE
LVPQQLAH
TETQEKNPLPSKETIEQEK
PGVTVKDVNQQEFVR
VSEADSSNADVWTK
DGQVINETSQHHDDLE
VEYGFQVK
WLHPNYSQV0IGLIK
LVDKFLEDJKK
AQLGGPEAAKSDETAAK
KVESLQEEIAFLKK
DIGFIKLD
FDHVITNM[OX)NNNYEPR
RVVNFIYVFHTLGQYFQKLGR
ESKKEDLVFIFWAPESAPU<
DPG1VANKKEEEDLAK
YDLDFKSPDDPSR
FLPSELRDEH
IEDGFSU<
ILTLTYVDKLIDDVHR
Those peptides presented at last year ASCO, especially those that only exists in cancer cells and are absent from normal cells are diamonds. Many neo-peptide cancer vaccine companies are dreaming to own them. Keep in mind far less 1% of neo-peptide can trigger anti-tumor immune response. The ones dendritic cells present to t cells will certain trigger t cells to kill cancer cells.
Finding neo-peptide that can trigger immune response is exactly the reason that Moderna has a partnership with Immatics. I strongly suggest you read the Immatics webpage about how t-cells can attack t-cells.
https://investors.modernatx.com/news/news-details/2023/Moderna-and-Immatics-Announce-Strategic-Multi-Platform-Collaboration-to-Develop-Innovative-Oncology-Therapeutics/default.aspx
https://immatics.com/t-cells-and-solid-tumors/
The strategic R&D collaboration between Moderna and Immatics focuses on three pillars:
*Applying Moderna's mRNA technology for in vivo expression of Immatics' next-generation, half-life extended TCR bispecifics (TCER®) targeting cancer-specific HLA-presented peptides.
*Enabling the discovery and development of novel mRNA-based cancer vaccines by leveraging Moderna's deep knowledge of mRNA science and customized information from Immatics' wealth of tumor and normal tissue data included in the target discovery platform XPRESIDENT® and its bioinformatics and AI platform XCUBE™.
*Evaluating Immatics' IMA203 TCR-T therapy targeting PRAME in combination with Moderna's PRAME mRNA-based cancer vaccine. The collaboration contemplates conducting preclinical studies and a Phase 1 clinical trial evaluating the safety and efficacy of the combination with the objective of further enhancing IMA203 T cell responses.
The following figure is the FDA approved ADCs. ADCs are not something new. It is only in the last a couple of years that BPs rekindle their interest in ADCs. As a matter of fact, the timeline should be after the data lock of the p3 trial. Have you seen AZN is going to invest $1.5b to manufacture ADCs? All the BPs have their ADC programs now. ADCs are bio missiles. To hit target accurately while keeping intact normal tissues, those ADCs need precise target information. Guess which platform can provide the precise target information? DCVax-L. If you have any doubt, find the encoded genes related to each of the approved ADCs, search in the data Dr. Liau uploaded, and check the variation of those overexpressed mutations before and after DCVax-L + poly-iclc treatment.
As today, even without any approval, simply using DCVax-L platform to supply neo-peptides and targets for ADCs, LP can make NWBO have a market cap of billions of dollars.
Now do you still think I should worry about being broke?
https://www.nature.com/articles/s41587-024-02168-5
